ESSA Pharma

EPIX NASDAQ
2.380
+0.075
+3.27%
Closed 16:00 06/20 EDT
Open
2.370
Prev Close
2.305
High
2.400
Low
2.370
Volume
2.12K
Avg Vol (3M)
7.46K
52 Week High
4.500
52 Week Low
1.870
% Turnover
0.03%
Market Cap
15.02M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers ESSA Pharma EPIX stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

ESSA Pharma Inc. is a Canada-based clinical-stage development pharmaceutical company. The Company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer (CRPC). The Company is developing drugs, which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR). The Company's product candidate, EPI-506 is a selective, oral small molecule pro-drug that blocks the N-terminal domain of the AR. EPI-506 is a pro-drug of EPI-002, a stereoisomer of the Company's discovery compound, EPI-001. The Company is conducting a Phase I/II clinical study to determine the safety, tolerability, maximum tolerated dose, pharmacokinetics and efficacy of EPI-506 in patients with metastatic CRPC. It is focused on developing EPI-506 as its clinical-development product candidate. ESSA Pharmaceuticals Corp. is the Company's subsidiary. The Company has not generated any revenues.
MORE >

Recently

Name
Price
%Change